Johnson and Johnson: The subcutaneous formulation of Rybrevant was more effective than the intravenous formulation in reducing the risk of death in lung cancer patients.
The subcutaneous injectable version of Rybrevant significantly reduced the risk of death compared to intravenous Rybrevant when used in combination ...
